INDIA GLYCOLS LIMITED

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/2026-27/73

2nd November, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 500201

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

Symbol: INDIAGLYCO

Dear Sirs,

Sub.: Material Update in Connection with Ennature Bio Pharma Limited with reference to Observation letter no. NSE/LIST/48932 dated 17th November, 2025 and no. DCS/AMAL/TS/R37/3905/2025-26 dated 19th November, 2025 ("Observation Letters"), issued by the National Stock Exchange of India Limited and BSE Limited (collectively the "Stock Exchanges"), respectively, received in relation to the Scheme of Arrangement.

With reference to captioned above, we would like to inform you that Ennature Bio Pharma Limited ("EBL"), through its letter dated 2nd November, 2026, has communicated to the Company certain material events/ updates in relation to EBL, which is enclosed herein as **Annexure A**.

This disclosure is being made in respect of EBL, pursuant to the requirement in the Observation Letters and SEBI Master Circular No. HO/491l 411 4(7)2025-CFD-POD21l 13762/2026 dated 30th January, 2026 (as amended).

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
For **India Glycols Limited**

ANKUR JAIN
Digitally signed by ANKUR JAIN
Date: 2026.11.02 23:04:17 +05'30'

Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a

Date: November 02, 2026

To,
India Glycols Limited
Plot No. 2-B & 2-C,
Sector – 126, Noida,
Uttar Pradesh – 201304

Subject: Intimation regarding receipt of Listing and Trading Approvals in connection with the Scheme of Arrangement amongst India Glycols Limited ("Demerged Company"), Ennature Bio Pharma Limited ("Resulting Company 1") and IGL Spirits Limited ("Resulting Company 2") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme").

Dear Sir/Madam,

This is to inform you that **Ennature Bio Pharma Limited ("EBPL")** has received the Listing and Trading Approvals from BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on November 02, 2026, in respect of the Equity Shares issued and allotted pursuant to the Scheme.

The relevant details are as under:

- **Name of the Stock Exchanges:** BSE and NSE
- **Type of Approval:** Listing and Trading Approval
- **Security Type:** Equity Shares
- **Number of Shares Listed:** 2,23,42,255 equity shares of Rs. 5/- each
- **Date of Approval:** November 02, 2026
- **Date of Commencement of Trading:** November 04, 2026

Copies of the Listing and Trading Approval letters received are available on the websites of BSE and NSE at https://www.bseindia.com/markets/marketinfo/noticescirculars?id=0 and https://www.nseindia.com/resources/exchange-communication-circulars respectively.

You are requested to kindly take the above information on record.

Thanking You.
For Ennature Bio Pharma Limited

PREETI CHOUDHARY
Digitally signed by PREETI CHOUDHARY
Date: 2026.11.02 22:12:40 +05'30'

Preeti Choudhary
Company Secretary